Luxembourg's Ministry of State, Ministry of Health and High Commission for National Protection (Haut-commissariat à la Protection nationale - HCPN) have unveiled details of the deployment of COVID-19 vaccines in the Grand Duchy.
The relevant authorities confirmed that the stock of COVID-19 vaccine doses continues to increase gradually. With the arrival of the first doses of the Moderna vaccine added to those of the Pfizer / BioNTech vaccine which arrived earlier, the vaccination campaign is continuing with good momentum, according to the authorities. In addition, the European Commission has succeeded in negotiating an order for 300 million additional doses of the Pfizer / BioNTech vaccine and the AstraZeneca vaccine is expected to receive its marketing authorisation at the end of January 2021.
The various components of Luxembourg's vaccine strategy are closely and continuously supported by the Ministry of Health and the HCPN through a dedicated working group. The supply axis is at the centre of the efforts of this working group, which liaises with the European Commission's “COVID vaccines” steering committee and vaccine manufacturers.
The tables pictured reflect the dose allocations to which Luxembourg is theoretically entitled according to the pro rata of 0.14% of the population as provided for in the contracts already concluded by the European Commission with the various manufacturers, as well as the allocations already delivered to the Grand Duchy to date and those which are expected by the end of March 2021.
The allocations shown in the table above are only theoretical; the final allocations will be announced by the manufacturers at the time of the conditional authorisation granted by the European Medicines Agency (EMA), based on the delivery and production capacities that exist at the given time.
In any case, it is expected that there will be enough doses of the various vaccines to vaccinate the following number of people:
- AstraZeneca: 207,524 people (415,048 doses)
- Janssen (Johnson&Johnson): 276,156 people (276,156 doses)
- Pfizer / BioNTech: 337,645 people (675,290 doses)
- Curevac: 164,700 people (329,399 doses)
- Moderna: 55,231 people (110,462 doses)
- Sanofi-GSK (contract with European Commission not yet concluded): 210,000 people (420,000 doses).
This represents a total number of 2,226,355 vaccine doses, which would enable (in theory) the vaccination of 1,251,256 individuals in Luxembourg.
The allocations shown in the table below are likely to be adjusted from week to week according to the production capacities of the manufacturers.
To date, Luxembourg has received a total of 14,625 doses of the Pfizer / BioNTech vaccine (first delivery of 9,750 on 28 December 2020 and second delivery of 4,875 on 11 January 2021) and 1,200 doses of the Moderna vaccine (delivered on 11 January). The next deliveries are scheduled for 18 January (4,875 doses of Pfizer / BioNTech), 25 January (3,900 doses of Pfizer / BioNTech and 1,200 doses of Moderna), 1 February (4,875 doses of Pfizer / BioNTech and 1,200 doses of Moderna), 8 February (4,875 doses of Pfizer / BioNTech), 15 February (4,875 doses of Pfizer / BioNTech and 4,800 doses of Moderna), 22 February (4,875 doses of Pfizer / BioNTech), 1 March (5,850 doses of Pfizer / BioNTech), 8 March (5,850 doses of Pfizer / BioNTech), 15 March (5,850 doses of Pfizer / BioNTech), 22 March (7,800 doses of Pfizer / BioNTech) and 29 March (9,750 doses of Pfizer / BioNTech). This brings the total number of confirmed vaccine doses to 86,400 until the end of March 2021.
